Research Analysts’ Weekly Ratings Updates for BioNTech (BNTX)

Several analysts have recently updated their ratings and price targets for BioNTech (NASDAQ: BNTX):

• 11/26/2024 – BioNTech had its price target lowered by analysts at JPMorgan Chase & Co. from $124.00 to $122.00. They now have a “neutral” rating on the stock.
• 11/19/2024 – BioNTech was upgraded by analysts at Evercore ISI from an “in-line” rating to an “outperform” rating. They now have a $125.00 price target on the stock, up previously from $110.00.
• 11/19/2024 – BioNTech is now covered by analysts at Berenberg Bank. They set a “buy” rating and a $130.00 price target on the stock.
• 11/18/2024 – BioNTech had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $150.00 price target on the stock.
• 11/14/2024 – BioNTech had its “buy” rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $171.00 price target on the stock.
• 11/8/2024 – BioNTech was upgraded by analysts at The Goldman Sachs Group, Inc. from a “neutral” rating to a “buy” rating. They now have a $137.00 price target on the stock, up previously from $90.00.
• 11/5/2024 – BioNTech had its price target lowered by analysts at TD Cowen from $132.00 to $122.00. They now have a “hold” rating on the stock.
• 11/4/2024 – BioNTech had its price target lowered by analysts at JPMorgan Chase & Co. from $125.00 to $124.00. They now have a “neutral” rating on the stock.
• 10/21/2024 – BioNTech had its price target raised by analysts at TD Cowen from $85.00 to $132.00. They now have a “hold” rating on the stock.
• 10/7/2024 – BioNTech had its price target raised by analysts at HSBC Holdings plc from $97.00 to $136.00. They now have a “buy” rating on the stock.
• 10/7/2024 – BioNTech had its price target raised by analysts at HC Wainwright from $113.00 to $150.00. They now have a “buy” rating on the stock.

BioNTech Trading Down 1.8 %

BNTX traded down $2.22 during mid-day trading on Tuesday, reaching $118.54. The stock had a trading volume of 771,418 shares, compared to its average volume of 817,223. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The stock has a market capitalization of $28.42 billion, a P/E ratio of -56.45 and a beta of 0.26. The firm’s fifty day simple moving average is $113.54 and its two-hundred day simple moving average is $98.00. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. The company had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm’s revenue was up 38.9% compared to the same quarter last year. During the same period last year, the company earned $0.73 earnings per share. On average, equities analysts predict that BioNTech SE will post -3.68 EPS for the current year.

Institutional Investors Weigh In On BioNTech

Several hedge funds have recently bought and sold shares of BNTX. GAMMA Investing LLC increased its holdings in shares of BioNTech by 86.9% during the second quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock worth $41,000 after purchasing an additional 238 shares during the period. EverSource Wealth Advisors LLC increased its stake in BioNTech by 106.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after acquiring an additional 252 shares during the period. Planning Capital Management Corp raised its holdings in BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after acquiring an additional 450 shares in the last quarter. Blue Trust Inc. lifted its position in shares of BioNTech by 491.1% during the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after acquiring an additional 388 shares during the period. Finally, Daiwa Securities Group Inc. grew its holdings in shares of BioNTech by 430.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company’s stock worth $155,000 after purchasing an additional 1,562 shares in the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.